Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAY0221
- Development stage
- Preclinical
- Lead developer
- Raynovent Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RAY0221 is an investigational small molecule Glucagon-like peptide 1 receptor (GLP-1R) agonist being developed by Raynovent Biotechnology (a subsidiary of Guangdong Zhongsheng Pharmaceutical). It is designed for the treatment of metabolic disorders, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). As a small molecule agonist, RAY0221 is intended to provide an oral alternative to traditional injectable GLP-1 therapies, leveraging the established mechanism of GLP-1R activation to improve glycemic control, promote weight loss, and potentially address liver inflammation and fibrosis. The drug is currently in the IND-enabling stage of development.
02
Targets
Beyond the preview
Go deeper on RAY0221.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAY0221.